FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
Executive Summary
Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.